Emmessar Biotech & Nutrition Analysis

dividend

Pros

Cons

• Unable to evaluate Emmessar Biotech & Nutrition's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate Emmessar Biotech & Nutrition's dividend against the top 25% market benchmark as the company has not reported any payouts.

health

Pros

• Emmessar Biotech & Nutrition is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Emmessar Biotech & Nutrition is profitable, therefore cash runway is not a concern.
• Emmessar Biotech & Nutrition is profitable, therefore cash runway is not a concern.
• Emmessar Biotech & Nutrition has no debt, it does not need to be covered by operating cash flow.
• Emmessar Biotech & Nutrition has no debt, it does not need to be covered by short term assets.
• Emmessar Biotech & Nutrition's cash and other short term assets cover its long term commitments.
• Emmessar Biotech & Nutrition currently has no debt however we can't compare to 5 years ago as we have no data for that period.
• Emmessar Biotech & Nutrition has no debt, therefore coverage of interest payments is not a concern.
• Emmessar Biotech & Nutrition has no debt.

Cons

• High level of physical assets or inventory.

management

Pros

• MSR's remuneration is lower than average for companies of similar size in India.
• MSR's compensation has been consistent with company performance over the past year, both up more than 20%.

Cons

misc

Pros

Cons

• Emmessar Biotech & Nutrition is not covered by any analysts.

past

Pros

• Emmessar Biotech & Nutrition's 1-year earnings growth exceeds its 5-year average (48.7% vs 39.9%)
• Emmessar Biotech & Nutrition has delivered over 20% year on year earnings growth in the past 5 years.
• Emmessar Biotech & Nutrition used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
• Emmessar Biotech & Nutrition has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
• Emmessar Biotech & Nutrition has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
• Emmessar Biotech & Nutrition's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (48.7% vs 22.7%).

Cons

value

Pros

• Emmessar Biotech & Nutrition is good value based on assets compared to the IN Pharmaceuticals industry average.
• Emmessar Biotech & Nutrition is good value based on earnings compared to the IN Pharmaceuticals industry average.
• Emmessar Biotech & Nutrition is good value based on earnings compared to the India market.
• BSE:524768 is up 6.3% along with the Pharmaceuticals industry (6.8%) over the past month.

Cons

• Emmessar Biotech & Nutrition's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
• Emmessar Biotech & Nutrition's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
• 524768 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
• 524768 underperformed the Market in India which returned -14.5% over the past year.
• BSE:524768 is up 6.3% underperforming the market in India which returned 8% over the past month.